VAXCYTE, INC. Asset Impairment Charges
VAXCYTE, INC. (PCVX) reported Asset Impairment Charges of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2025-02-25
- VAXCYTE, INC. asset impairment charges for the quarter ending 2023-12-31 was $0.00.
- VAXCYTE, INC. asset impairment charges for the quarter ending 2023-09-30 was $0.00.
- VAXCYTE, INC. asset impairment charges for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- VAXCYTE, INC. asset impairment charges for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- VAXCYTE, INC. asset impairment charges for fiscal 2024 was $0.00.
- VAXCYTE, INC. asset impairment charges for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- VAXCYTE, INC. asset impairment charges for fiscal 2022 was $200.00K.
- VAXCYTE, INC. asset impairment charges for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 6 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month | Asset Impairment Charges 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-25 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | -$13.00K derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | -$13.00K derived: sum of 3 quarters · filed 2025-02-25 | -$13.00K derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | -$13.00K derived: sum of 2 quarters · filed 2025-02-25 | -$13.00K derived: sum of 3 quarters · filed 2025-02-25 | $143.00K derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$13.00K derived: sum of 2 quarters · filed 2025-02-25 | $143.00K derived: sum of 3 quarters · filed 2025-02-25 | $200.00K 10-K · filed 2025-02-25 | $213.00K 10-K · filed 2023-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $156.00K derived: sum of 2 quarters · filed 2023-11-06 | $213.00K 10-Q · filed 2023-11-06 | $213.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $213.00K 10-Q · filed 2023-08-08 | $213.00K derived: sum of 3 quarters · filed 2024-02-27 | $213.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $57.00K 10-Q · filed 2023-05-08 | $57.00K derived: sum of 2 quarters · filed 2024-02-27 | $57.00K derived: sum of 3 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $267.00K 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $267.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $267.00K 10-Q · filed 2021-08-11 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |